A042520 Stock Overview
Engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
HansBiomed Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩8,500.00 |
| 52 Week High | ₩16,600.00 |
| 52 Week Low | ₩6,500.00 |
| Beta | 0.68 |
| 1 Month Change | -4.39% |
| 3 Month Change | 3.91% |
| 1 Year Change | -27.54% |
| 3 Year Change | -31.45% |
| 5 Year Change | -66.93% |
| Change since IPO | 34.71% |
Recent News & Updates
HansBiomed Corporation's (KOSDAQ:042520) Low P/S No Reason For Excitement
Dec 09
Is HansBiomed (KOSDAQ:042520) A Risky Investment?
Oct 29Recent updates
HansBiomed Corporation's (KOSDAQ:042520) Low P/S No Reason For Excitement
Dec 09Is HansBiomed (KOSDAQ:042520) A Risky Investment?
Oct 29Is HansBiomed (KOSDAQ:042520) A Risky Investment?
Feb 29HansBiomed Corporation (KOSDAQ:042520) Shares Fly 25% But Investors Aren't Buying For Growth
Feb 29Are Dividend Investors Making A Mistake With HansBiomed Corporation (KOSDAQ:042520)?
Apr 10Does HansBiomed (KOSDAQ:042520) Have A Healthy Balance Sheet?
Mar 06HansBiomed's(KOSDAQ:042520) Share Price Is Down 63% Over The Past Three Years.
Jan 30Are HansBiomed's (KOSDAQ:042520) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Dec 08
Declining Stock and Decent Financials: Is The Market Wrong About HansBiomed Corporation (KOSDAQ:042520)?
Nov 20Shareholder Returns
| A042520 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -2.7% | 2.2% | 0.5% |
| 1Y | -27.5% | 30.3% | -5.3% |
Return vs Industry: A042520 underperformed the KR Biotechs industry which returned 30.7% over the past year.
Return vs Market: A042520 underperformed the KR Market which returned -4.9% over the past year.
Price Volatility
| A042520 volatility | |
|---|---|
| A042520 Average Weekly Movement | 7.4% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in KR Market | 13.0% |
| 10% least volatile stocks in KR Market | 3.5% |
Stable Share Price: A042520 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A042520's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 127 | Guen Young Kim | www.hansbiomed.com |
HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralized cortical bone stick; SureChip, a cancellous bone chip; OsteoGrow, a demineralized bone matrix inserter; BellaCell HD, an allograft dermal product that transplanted in a patient whose skin has been lost due to breast cancer; and SureDerm, an acellular dermal matrix. It also offers BELLAGEL, a breast prosthesis, internal, and gel-filled solution; MINT Lift, a PDO thread; EZ-Tcon solution; Lion HT/HN, a hair transplanter body/needle; and Scar Clinic, a scar management solution.
HansBiomed Corporation Fundamentals Summary
| A042520 fundamental statistics | |
|---|---|
| Market cap | ₩110.39b |
| Earnings (TTM) | -₩7.22b |
| Revenue (TTM) | ₩81.14b |
1.4x
P/S Ratio-15.3x
P/E RatioIs A042520 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A042520 income statement (TTM) | |
|---|---|
| Revenue | ₩81.14b |
| Cost of Revenue | ₩29.39b |
| Gross Profit | ₩51.75b |
| Other Expenses | ₩58.97b |
| Earnings | -₩7.22b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -556.17 |
| Gross Margin | 63.78% |
| Net Profit Margin | -8.90% |
| Debt/Equity Ratio | 51.1% |
How did A042520 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 05:01 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HansBiomed Corporation is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jong Kyung Choi | DAOL Investment & Securities Co., Ltd. |
| Sang-Hun Lee | iM Securities |
| Seung Kyu Jung | Kiwoom Securities Co., Ltd. |